Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332404 | 0.84 | CA12 (0.47) | CYP3A4ALDH1A1RECQLCA12CA1 | |
| SCHEMBL17941841 | 0.80 | APP (0.47) | KDM4EAPPMAPK1 | |
| SCHEMBL9264667 | 0.79 | NQO1 (0.50) | SMN1; SMN2ALDH1A1GAACA12CA1 | |
| SCHEMBL3583760 | 0.73 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1GAALMNAKDM4E | |
| SCHEMBL731371 | 0.72 | CA1 (0.43) | CYP3A4ALDH1A1RECQLGAACA12 | |
| SCHEMBL244083 | 0.72 | PKM (0.36) | SMN1; SMN2ALDH1A1GAAGPR84MEN1 | |
| SCHEMBL48239 | 0.71 | ALDH1A1 (0.75) | CYP3A4SMN1; SMN2NR1I2ALDH1A1RECQL | |
| SCHEMBL28106819 | 0.71 | ALDH1A1 (0.75) | CYP3A4SMN1; SMN2NR1I2ALDH1A1RECQL | |
| P-Xylene SCHEMBL6845696 | 0.70 | ALDH1A1 (0.60) | CYP3A4SMN1; SMN2NR1I2ALDH1A1RECQL | |
| SCHEMBL82830 | 0.70 | ALDH1A1 (0.60) | CYP3A4SMN1; SMN2NR1I2ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155401-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-05 | — | — | US | disclosed |
| US-8653109-B2 | Substituted bipyridine derivatives and their use as adenosine receptor ligands | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20100093728-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093728-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | CYP3A4 895/4885SMN1; SMN2 4426/4885NR1I2 425/4885 |
| US-20140155401-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | CYP3A4 895/4885SMN1; SMN2 4426/4885NR1I2 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.